Quetiapine Augmentation in Severe Obsessive Compulsive Disorder
Phase 3
Completed
- Conditions
- Obsessive Compulsive Disorder
- Registration Number
- NCT00254735
- Lead Sponsor
- AstraZeneca
- Brief Summary
The purpose of the study is to evaluate the efficacy of quetiapine or placebo added to baseline treatment of SSRI/clomipramine for the treatment of OCD in adult subjects.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 44
Inclusion Criteria
- Signed informed consent, men and women aged ³18 to £65 years with diagnosis of OCD, at least 12 weeks of treatment with SSRI or clomipramine
Exclusion Criteria
- Substance abuse or dependence, female patients who are pregnant, lactating or at risk of pregnancy, known intolerance or lack of response to quetiapine, use of antihypertensive medication with changing doses
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Absolute change of OCD symptoms from baseline to endpoint on the total Y-BOCS score.
- Secondary Outcome Measures
Name Time Method Change of comorbid psychiatric symptoms and measures of quality of life from baseline to endpoint documented by different scales. Evaluation of the safety and tolerability profile of quetiapine compared to placebo added to a baseline medication of SSRI/clomipramine.
Trial Locations
- Locations (1)
Research Site
🇩🇪Lübeck, Germany